Regional variability in changes in 5-HT2A receptor mRNA levels in rat brain following irreversible inactivation with EEDQ 1

Molecular Brain Research

Volumn 39, Issue 1-2, 1996, Pages 198-206

  Raghupathi, Revathi K ^a   Artymyshyn, Roman ^a   McGonigle, Paul ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

5 HT2A mRNA; 5 HT2A receptor; Autoradiography; Hybridization, in situ; N ethoxycarbonyl 2 ethoxy 1,2 dihydroquinoline; Receptor regulation

Indexed keywords

2 ETHOXY 1(2H) QUINOLINECARBOXYLIC ACID ETHYL ESTER; KETANSERIN; MESSENGER RNA; PHOSPHORUS; SEROTONIN 2A RECEPTOR; TRITIUM;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; CAUDATE NUCLEUS; CLAUSTRUM; CONTROLLED STUDY; MALE; NONHUMAN; PHARMACOLOGY; PHYSIOLOGY; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR BLOCKING; RNA PROBE; TRANSCRIPTION REGULATION;

ANIMALS; AUTORADIOGRAPHY; BRAIN; MALE; QUINOLINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RNA, MESSENGER; SEROTONIN ANTAGONISTS;

ANIMALIA; TRITIUM;

EID: 0029938668     PISSN: 0169328X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0169-328X(96)00024-1     Document Type: Article

References (46)

1. 2 receptor stimulation, Mol. Pharmacol., 43 (1993) 349-355.
2. 2 mRNA and receptor levels in the striatum and nucleus accumbens of the rat. Mol. Brain. Res., 11 (1991) 161-166.
3. 125I autoradiography. J. Neurosci. Methods, 32 (1990) 185-192.
4. 2 receptor recovery in mature and senescent rat brain after irreversible receptor modification: effect of chronic reserpine treatment, J. Pharmacol. Exp. Ther., 243 (1987) 69-75.
5. 2 serotonin receptor recovery, J. Neurochem., 46 (1986) 589-593.
6. Belleau, B., DiTullio, V. and Godin, D., The mechanism of irreversible adrenergic blockade by N-carbethoxydihydroquinolines. Model studies with typical serine hydrolases. Biochem. Pharmacol., 18 (1969) 1039-1044.
7. 2 receptor mRNA in response to haloperidol treatment: a quantitative in situ hybridization study. Neuroscience, 45 (1991) 117-126.
8. Blackshear, M.A., Steranka, L.R. and Sanders-Bush, E., Multiple serotonin receptors: regional distribution and effect of raphe lesions. Eur. J. Pharmacol., 76 (1981) 325-334.
9. 2 receptors and serotonergic axons in rat neocortex. Brain Res., 453 (1988) 315-328.
10. 2 receptors. Life Sci., 42 (1988) 2439-2445.
11. 2 receptor mRNA in rat frontal cortex, J. Neurochem., 61 (1993) 1270-1276.
12. Carman, J.S., Ahdieh, H., Wyaat-Knowles, E., Warga, E. and Panagides, J., A controlled study of mianserin in moderately to severely depressed outpatients. Psychopharmacol. Bull., 27 (1991) 135-139.
13. Ceulemans, D.L.S., Hoppenbrouwers, M.-L.J.A., Gelders, Y.G. amd Reyntjens, A.J.M., The influence of ritanserin, a serotonin antagonist, in anxiety disorders: a double-blind placebo-controlled study versus lorazepam. Pharmacopsychiatry, 18 (1985) 303-305.
14. Chang, K.J., Moran, J.F. and Triggle, D.J., Mechanism of cholinergic antagonism by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ). Pharmacol. Res. Commun., 2 (1970) 63-66.
15. Conn, P.J. and Sanders-Bush, E., Central serotonin receptors: effector systems, physiological roles and regulation, Psychopharmacology, 92 (1987) 267-277.
16. Darchen, F., Scherman, D., Laduron, P.M. and Henry, J. -P., Ketanserin binds to the monoamine transporter of chromaffin granules and of synaptic vesicles. Mol. Pharmacol., 33 (1988) 672-677.
17. 2 and beta-adrenergic receptors following noradrenergic or serotonergic denervation. J. Neural Transm., 44 (1989) 1419-1427.
18. 2A receptors in P11 cells through a post-transcriptional mechanism requiring activation of protein kinase C. J. Biol. Chem., 269 (1994) 31850-31857.
19. 2 receptors throughout the rat central nervous system using quantitative autoradiography. Brain Res., 421 (1987) 263-279.
20. Frazer, A., Offord, S.J. and Lucki, I., Regulation of serotonin receptors and responsiveness in the brain. In: E. Sanders-Bush (Rd.), The Serotonin Receptors, Humana Press, 1988, pp. 319-362.
21. Gelders, Y.G., Thymosthenic agents, a novel approach in the treatment of schizophrenia. Br. J. Psychiat., Suppl. 11 (1989) 33-36.
22. Gozlan, H., Laporte, A.-M., Thibault, S., Schechter, L.E., Bolanos, F. and Hamon, M., Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain, Neuropharmacology, 33 (1994) 423-431.
23. Hadcock, J.R., Wang, H.-Y. and Malbon, C.C., Agonist-induced destabilization of β-adrenergic receptor mRNA. J. Biol. Chem., 264 (1989) 19928-19933.
24. 2 receptor mRNA expression in rat brain. Neuroscience, 47 (1992) 771-779.
25. 2 dopamine receptor mRNA synthesis in a 6-hydroxydopamine parkinsonian rat model. Brain Res. Bull., 28 (1992) 697-701.
26. 1 receptor binding and mRNA in rat brain using receptor autoradiographic and in situ hybridization techniques. Neuroscience, 45 (1991) 359-371.
27. 2 dopamine receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo: selective protection by neuroleptics. J. Pharmacol. Exp. Ther., 233 (1985) 656-662.
28. 2 receptor by in situ hybridization histochemistry. Correlation with the distribution of receptor sites. Brain Res., 524 (1990) 139-143.
29. Paxinos, G. and Watson, C., The Rat Brain in Stereotaxic Coordinates, Academic Press, Orlando, FL, 1986.
30. Pazos, A., Cortes, R. and Palacios, J.M., Quantitative autoradiographic mapping of serotonin receptors in rat brain. II. Serotonin-2 receptors. Brain Res., 346 (1985) 231-249.
31. Pinto, W. and G. Battaglia., In vivo EEDQ dose-dependently inactivates rat brain 5-HT receptors but not 5-HT uptake sites. NeuroReport, 5 (1993) 61-64.
32. 2C receptors. Mol. Brain Res., 23 (1994) 163-178.
33. 2 receptors in rat cortex. Studies with a putative selective agonist and an antagonist, Biochem. Pharmacol., 45 (1991) 1099-1105.
34. 2 receptor, EMBO J., 7 (1988) 4135-4140.
35. 2 receptors in rat midbrain. Eur. J. Pharmacol., 90 (1983) 377-384.
36. 1A receptor mRNA after irreversible inactivation with EEDQ, Mol. Brain Res., (1996) in press.
37. 2 receptor antagonist, Eur. J. Pharmacol., 246 (1993) 73-80.
38. 2 receptors in mouse brain, Mol. Phamacol., 43 (1992) 84-89.
39. 2 receptor antagonist, J. Biol. Chem., 269 (1994) 396-401.
40. 2 receptor mRNA in rat striatum by chronic neuroleptic treatment. Eur. J. Pharmacol., 207 (1991) 165-168.
41. 2 receptor mRNA levels, Eur. J. Pharmacol.: Mol. Biol. Section, 207 (1991) 169-172.
42. 1C mRNA and receptor levels, Dev. Brain Res., 58 (1991) 51-58.
43. Roth, B.L., Nakaki, T., Chuang, D.-M. and Costa, E., Aortic recognition sites for serotonin (5-HT) are coupled to phospholipase C and modulate phosphatidylinositol turnover. Neuropharmacology, 23 (1984) 1223-1225.
44. Spurlock, G., Buckland, P., O'Donovan, M. and McGuffin, P., Lack of effects of antidepressant drugs on the levels of mRNAs encoding serotonergic receptors, synthetic enzymes and 5-HT transporter, Neuropharmacology, 3 (1994) 433-440.
45. Toth, M. and Shenk, T., Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transcription, Mol. Pharmacol., 45 (1994) 1095-1100.
46. 2 dopamine receptor mRNA during ontogenesis, lesion and chronic antagonist treatment. Life Sci., 50 (1991) 383-396.